CDI 988
Alternative Names: CDI-988Latest Information Update: 23 Jul 2024
At a glance
- Originator Cocrystal Pharma Inc
- Class Antivirals; Small molecules
- Mechanism of Action 3C viral protease inhibitors; Coronavirus 3C-like proteinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I COVID 2019 infections; Norovirus infections
Most Recent Events
- 18 Jul 2024 Adverse event data from a phase I trial in COVID-19 infections released by Cocrystal Pharma
- 04 Jan 2024 Preliminary adverse events data from a phase I trial in COVID-19 infections (In volunteers) released by Cocrystal Pharma
- 28 Aug 2023 Phase-I clinical trials in Norovirus infections (In volunteers) in Australia (PO) (Cocrystal Pharma pipeline, August 2023) (NCT05977140)